Halozyme Therapeutics stock hits all-time high at 109.69 USD
What it means
- What to watch: Healthcare upside usually comes in discrete events — readouts, approvals and launches — rather than gradual trends.
- How the stock is trading: $HALO -5.66% in the latest session.
- Timing: It landed after the closing bell, so the session change beside it was locked in before the story existed. The next session is the first that could react.
Where the stock stands
$HALO last traded at $122.96, -5.66% on the session. That puts it 8.2% shy of its 52-week high of $134.00 and 101% clear of its low of $61.23 — in the upper part of the range. Over the year it has ranged 119% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $HALO page.
How much coverage it is getting
Wook has logged 2 stories on $HALO in the last 30 days, 1 of them this week. At its 30-day pace you would expect less than one a week, so this week is running well ahead of normal; the press has found a reason to keep writing. Across those stories 1 read bullish, 1 neutral and 0 bearish. This one reads bullish, so it sits in step with most of the run. This is the only one from Investing.com; the rest came from other outlets. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
What to watch next
The $HALO page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. And Wook AI, up top, will happily do the math — how far $HALO sits from its high, or how this week's coverage stacks up.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. It reads bullish at medium severity because of “high” and “all-time high” in the wording, with nothing on the bearish side to offset them. It was matched to $HALO. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 2, 2026. $HALO has moved +11.01% ($110.76 to $122.96). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.